Search Results

At Teva we believe that everyone should have access to safe quality medicine that helps manage disease fights infection or simply improves overall health

Cory Wohlbach is responsible for steering Teva s new biosimilar products through the regulatory approval process He explains what biosimilars are how they have the potential to reduce costs for patients and how patient safety is always a top priority

We explain why generic medicines are an essential part of modern healthcare and look at the research development processes and logistical challenges involved in creating them

Clinical trials are essential for the development of medicines and it s increasingly recognised there is a growing need for diversity in these trials Teva investigates why and outlines how it is working to increase diverse representation in clinical trials

Most people know what generic medicines are products created to be the same as branded drugs whose patents have expired

Teva s ESG strategy guides how we advance health and equity minimize our impact on the planet and dedicate ourselves to quality ethics and transparency It drives us to be responsible in all we do take a look at how this came to life in 2021